[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT1187611E - Composicoes oftalmicas de histamina e sua utilizacoes - Google Patents

Composicoes oftalmicas de histamina e sua utilizacoes

Info

Publication number
PT1187611E
PT1187611E PT00939556T PT00939556T PT1187611E PT 1187611 E PT1187611 E PT 1187611E PT 00939556 T PT00939556 T PT 00939556T PT 00939556 T PT00939556 T PT 00939556T PT 1187611 E PT1187611 E PT 1187611E
Authority
PT
Portugal
Prior art keywords
histamine
utilizations
ophthalmic compositions
ophthalmic
concentration
Prior art date
Application number
PT00939556T
Other languages
English (en)
Inventor
Kurt R Gehlsen
Original Assignee
Maxim Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharm Inc filed Critical Maxim Pharm Inc
Publication of PT1187611E publication Critical patent/PT1187611E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT00939556T 1999-06-03 2000-06-02 Composicoes oftalmicas de histamina e sua utilizacoes PT1187611E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13756499P 1999-06-03 1999-06-03

Publications (1)

Publication Number Publication Date
PT1187611E true PT1187611E (pt) 2004-10-29

Family

ID=22478011

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00939556T PT1187611E (pt) 1999-06-03 2000-06-02 Composicoes oftalmicas de histamina e sua utilizacoes

Country Status (11)

Country Link
US (1) US6531120B2 (pt)
EP (1) EP1187611B1 (pt)
AT (1) ATE273704T1 (pt)
AU (1) AU777655B2 (pt)
CA (1) CA2376108A1 (pt)
DE (1) DE60013126T2 (pt)
DK (1) DK1187611T3 (pt)
ES (1) ES2225156T3 (pt)
HK (1) HK1045458B (pt)
PT (1) PT1187611E (pt)
WO (1) WO2000074649A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303376A3 (en) 2001-02-28 2007-08-28 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists, and pharmaceutical compositions containing them and use thereof
US7012084B2 (en) 2001-02-28 2006-03-14 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
CA2453609C (en) 2001-07-18 2010-05-04 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
WO2003082081A2 (en) * 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage
JP2006505531A (ja) 2002-09-11 2006-02-16 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン−４受容体作働薬としてのピペラジン尿素誘導体
US7071211B2 (en) * 2002-09-27 2006-07-04 Bausch & Lomb Inc. Small organic molecules that increase the activity of gelatinase a in ocular cells
CN100434440C (zh) * 2002-12-02 2008-11-19 阿布格尼克斯公司 针对肿瘤坏死因子的抗体及其用途
DE10362141B4 (de) * 2003-03-19 2008-08-21 Johnson Controls Gmbh Feststell- und Neigungsverstellung für Beschläge
US20040248959A1 (en) * 2003-04-30 2004-12-09 Bender Scott C. Histamine containing eye drops for visual identification of lymphoid tissue within the tissues of the eye, that are to be samples for further diagnostic testing
JP4834829B2 (ja) * 2005-03-31 2011-12-14 国立大学法人山口大学 クラミジア属細菌の抑制に効果のあるトリプトファン代謝中間産物
WO2010020052A1 (en) * 2008-08-21 2010-02-25 Edouard Kouassi Methods and compounds for increasing red blood cell survival
CN104337760B (zh) * 2013-08-02 2018-09-04 山东新时代药业有限公司 一种二盐酸组胺注射液及其制备方法
CN110075063A (zh) * 2019-05-27 2019-08-02 合肥亿帆生物医药有限公司 一种二盐酸组胺注射液及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510145A (en) * 1980-12-02 1985-04-09 Schachar Ronald A Method for inhibiting contraction of ophthalmic wounds or incisions
US5679337A (en) * 1991-06-14 1997-10-21 Professional Pharmaceutical, Inc. Method and composition for topical treatment of Aphthous stomatitis histamine using phosphate as active ingredient
IL101441A (en) 1992-04-01 1999-07-14 Univ Ramot Pharmaceutical preparations for the treatment and prevention of diseases or irregularities in the eye
WO1993023010A1 (en) 1992-05-13 1993-11-25 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
US5401327A (en) 1993-06-18 1995-03-28 Wilmington Partners L.P. Method of treating contact lenses
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
EP0706394B1 (en) * 1994-03-02 2003-05-21 Professional Pharmaceutical, Inc. Use of a compostion comprising histamine phosphate for the manufacture of a medicament for the topical treatment of epithelial inflammation or lesions
US5861148A (en) 1995-01-23 1999-01-19 Smith; Stewart Gregory Ophthalmic compositions and process of using
US5895645A (en) 1995-01-31 1999-04-20 Bausch & Lomb Incorporated Opthalmic solution for artificial tears
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
AU2434297A (en) * 1996-05-23 1997-12-09 Alcon Laboratories, Inc. The use of 5-ht1b/1d agonists to treat ocular pain
AU4249297A (en) * 1996-10-31 1998-05-22 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6270781B1 (en) * 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors

Also Published As

Publication number Publication date
ES2225156T3 (es) 2005-03-16
EP1187611A2 (en) 2002-03-20
WO2000074649A3 (en) 2002-01-17
EP1187611B1 (en) 2004-08-18
ATE273704T1 (de) 2004-09-15
AU5462700A (en) 2000-12-28
WO2000074649A2 (en) 2000-12-14
CA2376108A1 (en) 2000-12-14
US6531120B2 (en) 2003-03-11
HK1045458A1 (en) 2002-11-29
AU777655B2 (en) 2004-10-28
DK1187611T3 (da) 2004-10-11
HK1045458B (zh) 2005-03-24
DE60013126T2 (de) 2005-09-08
DE60013126D1 (de) 2004-09-23
US20020098224A1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
MY129356A (en) Electrospun pharmaceutical compositions
EA200401009A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
PT1187611E (pt) Composicoes oftalmicas de histamina e sua utilizacoes
CZ2001449A3 (cs) Sloučeniny a prostředky pro dodávání aktivních látek
AU2274201A (en) Compounds and compositions for delivering active agents
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
DE69922676D1 (de) N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden
TR200102977T2 (tr) Yeni tedavi yöntemi.
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
BR0209020A (pt) Composição farmacêutica de polialilamina
DE60019334D1 (de) Antivirale arznei
MX9710206A (es) Composicion farmaceutica de amiodarone para administracion parenteral.
BR0012696A (pt) Composição oftálmica
SE9802208D0 (sv) Novel compounds
IT1255802B (it) Derivati imidazolici ad attivita' a ii antagonista
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
NZ514558A (en) Viral treatment
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
MY141012A (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
PT101444A (pt) Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao
DE60128100D1 (de) Analgetisches arzneimittel
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
IL126725A0 (en) Compositions comprising a nitrone compound for use in treating ocular inflammation
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
BR0008952A (pt) Composição de preparação de iodo